INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)

This project aims to evaluate the safety and efficacy of the antiplatelet regimen combining indobufen and clopidogrel in preventing ischemic events after stent-assisted coiling embolization and flow diverter implantation for intracranial aneurysms. Using a randomization system, patients with unruptured intracranial aneurysms scheduled for interventional treatment will be divided into an experimental group and a control group. Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively. Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively. An independent group of researchers will assess cerebrovascular thromboembolic events and bleeding events at different time points.

NCT Number	NCT07089862
Lead Sponsor	Beijing Tiantan Hospital Collaborators: RenJi Hospital, First Affiliated Hospital of Fujian Medical University, Jiangnan University Central Hospital, Beijing Chao Yang Hospital, Beijing Friendship Hospital, Beijing Shuyi Hospital, The Central Hospital of Lishui City
Conditions	Unruptured Intracranial Aneurysm, Indobufen
Enrollment	2,500 participants
Start Date	2025-08-31
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-16